ABSTRACT
The Office of Generic Drugs has ensured the high quality of generic products based upon two requirements: pharmaceutical equivalence and bioequivalence to the reference listed drug (RLD). This paradigm has been used with success toward ensuring quality generic drug products that provide the same therapeutic benefit as the RLD. Drug products have increased in design complexity; as a result, approaches to ensure therapeutic equivalence must evolve to provide assurance of quality generic drug products. The Food and Drug Administration quality by design initiative (QbD) provides an enhanced evaluation approach by introducing the concept of a quality target product profile (QTPP). The QTPP introduces, within the context of the current regulatory framework, the quality concept of “pharmaceutical equivalence by design.” This article illustrates through several examples how this QbD element in the evaluation of modified-release drug products enhances the current framework to ensure generic drug product equivalence. It achieves this by complementing the traditional paradigm, “equivalence by testing,” where product equivalence is based upon inferences from a limited bioequivalence study, to one that also considers whether the drug product was developed to be an equivalent to the RLD, using appropriate quality surrogates that target “pharmaceutical equivalence by design.”
Similar content being viewed by others
REFERENCES
Yu LX, Raw AS, Lionberger R, Rajagopalan R, Lee LM, Holcombe F, et al. US FDA question-based review for generic drugs: a new pharmaceutical quality assessment system. J Gen Med. 2007;4:239–48.
Woodcock J. The concept of pharmaceutical quality. American Pharmaceutical Review. 2004; Nov/Dec: 1–3.
Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) 2010, 30th Edition, pp. i–xx.
FDA Guidance for Industry: ICH Q8(R2) Pharmaceutical Development; November 2009.
Farinha A, Bica A, Pais JP, Toscano MC, Tavares P. Bioequivalence evaluation of two omeprazole formulations in humans. Eur J Pharm Sci. 1999;7:311–5.
Vaz-da-Siva M, Loureiro AI, Nunes T, Maia J, Tavares S, Falcao A, et al. Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. Clin Drug Investig. 2005;25(6):391–9.
Elkoshi Z, Behr D, Mirimsky A, Tsvetkov I, Danon A. Multiple-dose studies can be a more sensitive assessment than single-dose studies: the case with omeprazole. Clin Drug Investig. 2002;22(9):585–92.
Moore T, Smith A, Ye W, Te DY, Westenberger BJ, Lionberger R, et al. Generic omeprazole delayed release capsules: in-vitro performance evaluations. Drug Dev Ind Pharm. 2009;35(8):917–21.
Metadate CD® Label approved on April 16, 2009
Concerta® Label approved on November 4, 2009
Gonzalez MA, Pentikis HS, Anderl N, Benedict MF, DeCory HH, Dirksen SJH, et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther. 2002;40(4):175–84.
Swanson JM, Wigal SB, Wigal T, Sonuga-Burke E, Greenhill LL, Biederman J, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The Comac Study). Pediatrics. 2004;113(3):e206–16.
Hendeles L, Wubbena P, Weinberger M. Food-induced dose dumping of a once-a day theophylline. Lancet. 1984;2:1471.
FDA Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies; December 2002
Meyer RJ, Hussain AS. Awareness topic: mitigating the risks of ethanol induced dose dumping from oral sustained/controlled release dosage forms, FDA’s advisory committee for pharmaceutical sciences meeting; October 2005.
Safety Alerts for Human Medical Products (Fentanyl transdermal System CII Patches); 2008 April 19. Available from http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts
Marier JF, Lor M, Morin J, Roux L, Di Marco M, Morelli G, et al. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir information. Br J Clin Pharmacol. 2006;63(1):121–4.
Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25:781–91.
Lionberger R, Lee SL, Lee LM, Raw AS, Yu LX. Quality by design: concepts for ANDAs. AAPS J. 2008;10(2):268–76.
Chen ML, Lee VHL. Equivalence-by-design: targeting in-vivo drug delivery profile. Pharm Res. 2008;25(12):2723–30.
Draft Guidance for Industry: Bioequivalence Recommendations for Specific Products: Zolpidem Tablet Extended Release Tablets; August 2008
Letter to Richard Gural (Sanofi-Aventis) from Janet Woodcock FDA in response to Citizen Petition: 2007-P-0182; 2010 October 13. Available from www.regulations.gov
Draft Guidance for Industry: Bioequivalence Recommendations for Specific Products: Tramadol Tablet Extended Release Tablets; November 2007
Draft Guidance for Industry: Residual Drug in Transdermal and Related Drug Delivery Systems; August 2010
Author information
Authors and Affiliations
Corresponding author
Additional information
The views presented in this article do not necessarily reflect those of the Food and Drug Administration.
Rights and permissions
About this article
Cite this article
Raw, A.S., Lionberger, R. & Yu, L.X. Pharmaceutical Equivalence by Design for Generic Drugs: Modified-Release Products. Pharm Res 28, 1445–1453 (2011). https://doi.org/10.1007/s11095-011-0397-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-011-0397-6